GOALS OF WORK: Quality of life (QOL) is significantly impaired in patients with acute myeloid leukemia (AML), and fatigue is the most common and disabling symptom; effective treatment measures have yet to be found. Cytokines, biomarkers of inflammation, may moderate both health outcomes, but published data are limited. We looked at the role of cytokines in modulating QOL and fatigue in an older AML population. PATIENTS AND METHODS: We recruited 34 English-speaking patients (23 men, 11 women) aged 50 or older with AML within 1 year of diagnosis. QOL and fatigue were assessed with validated questionnaires. Blood was simultaneously drawn for quantitative measurement of a 13-cytokine panel. Repeat measurements were done 4-6 weeks later (n = 28 patients). Spearman correlations between health measures and cytokine levels were examined at baseline, as were changes in variables between time points. A potentially clinically important correlation was defined as an r > or = 0.30. RESULTS: At baseline, potentially clinically important correlations were noted between global QOL and interferon (IFN)-gamma (r = -0.376, p = 0.031), interleukin (IL)-2 (r = -0.340, p = 0.053), IL-5 (r = -0.368, p = 0.035), IL-8 (r = -0.312, p = 0.077), and TNF-alpha (r = -0.326, p = 0.064). A similar correlation was observed between IL-6 and fatigue (r = 0.332, p = 0.059). Between time points, there were no potentially important correlations between changes in global QOL and any cytokine. However, potentially important correlations with fatigue were seen with both IL-5 (r = 0.344, p = 0.073) and IL-10 (r = 0.326, p = 0.091) between time points. CONCLUSIONS: These preliminary data provide support for a larger controlled study of cytokines, fatigue, and QOL in patients with AML.
GOALS OF WORK: Quality of life (QOL) is significantly impaired in patients with acute myeloid leukemia (AML), and fatigue is the most common and disabling symptom; effective treatment measures have yet to be found. Cytokines, biomarkers of inflammation, may moderate both health outcomes, but published data are limited. We looked at the role of cytokines in modulating QOL and fatigue in an older AML population. PATIENTS AND METHODS: We recruited 34 English-speaking patients (23 men, 11 women) aged 50 or older with AML within 1 year of diagnosis. QOL and fatigue were assessed with validated questionnaires. Blood was simultaneously drawn for quantitative measurement of a 13-cytokine panel. Repeat measurements were done 4-6 weeks later (n = 28 patients). Spearman correlations between health measures and cytokine levels were examined at baseline, as were changes in variables between time points. A potentially clinically important correlation was defined as an r > or = 0.30. RESULTS: At baseline, potentially clinically important correlations were noted between global QOL and interferon (IFN)-gamma (r = -0.376, p = 0.031), interleukin (IL)-2 (r = -0.340, p = 0.053), IL-5 (r = -0.368, p = 0.035), IL-8 (r = -0.312, p = 0.077), and TNF-alpha (r = -0.326, p = 0.064). A similar correlation was observed between IL-6 and fatigue (r = 0.332, p = 0.059). Between time points, there were no potentially important correlations between changes in global QOL and any cytokine. However, potentially important correlations with fatigue were seen with both IL-5 (r = 0.344, p = 0.073) and IL-10 (r = 0.326, p = 0.091) between time points. CONCLUSIONS: These preliminary data provide support for a larger controlled study of cytokines, fatigue, and QOL in patients with AML.
Authors: J Paul Monk; Gary Phillips; Ross Waite; John Kuhn; Larry J Schaaf; Gregory A Otterson; Denis Guttridge; Chris Rhoades; Manisha Shah; Tamara Criswell; Michael A Caligiuri; Miguel A Villalona-Calero Journal: J Clin Oncol Date: 2006-04-20 Impact factor: 44.544
Authors: Vicki S Conn; Adam R Hafdahl; Davina C Porock; Roxanne McDaniel; Paul J Nielsen Journal: Support Care Cancer Date: 2006-01-31 Impact factor: 3.603
Authors: Andrea Schumacher; Dieter Wewers; Achim Heinecke; Cristina Sauerland; Olaf M Koch; Jürgen van de Loo; Thomas Büchner; Wolfgang E Berdel Journal: Leuk Res Date: 2002-04 Impact factor: 3.156
Authors: Sarah M Rausch; Brian D Gonzalez; Matthew M Clark; Christi Patten; Sara Felten; Heshan Liu; Yafei Li; Jeff Sloan; Ping Yang Journal: Lung Cancer Date: 2012-03-29 Impact factor: 5.705
Authors: Jordan D Hildenbrand; Debra M Davis; Areej El-Jawahri; Kris W Herring; Susan C Locke; Kathryn I Pollak; Gregory P Samsa; Karen E Steinhauser; Jesse D Troy; Peter A Ubel; Thomas W Leblanc Journal: Support Care Cancer Date: 2020-11-06 Impact factor: 3.603
Authors: Kah Poh Loh; Janet A Tooze; Barbara J Nicklas; Stephen B Kritchevsky; Jeff D Williamson; Leslie R Ellis; Bayard L Powell; Timothy S Pardee; Neha G Goyal; Heidi D Klepin Journal: J Geriatr Oncol Date: 2019-04-05 Impact factor: 3.599
Authors: Dounya Schoormans; Teodora Radonic; Piet de Witte; Maarten Groenink; Donija Azim; Rene Lutter; Barbara J M Mulder; Mirjam A G Sprangers; Aeilko H Zwinderman Journal: PLoS One Date: 2012-09-25 Impact factor: 3.240